Department of Biochemistry and Pharmacogenomics, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland.
1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland.
Int J Mol Sci. 2023 Aug 23;24(17):13095. doi: 10.3390/ijms241713095.
Aortic stenosis (AS) is the most prevalent primary valve lesion demanding intervention. Two main treatment options are surgical aortic valve replacement or transcatheter aortic valve implantation. There is an unmet need for biomarkers that could predict treatment outcomes and become a helpful tool in guiding Heart Team in the decision-making process. Micro-ribonucleic acids (microRNAs/miRs) have emerged as potential biomarkers thoroughly studied in recent years. In this review, we aimed to summarize the current knowledge about the role of miRNAs in AS based on human subject research. Much research investigating miRNAs' role in AS has been conducted so far. We included 32 original human subject research relevant to the discussed field. Most of the presented miRNAs were studied only by a single research group. Nevertheless, several miRNAs appeared more than once, sometimes with high consistency between different studies but sometimes with apparent discrepancies. The molecular aspects of diseases are doubtlessly exciting and provide invaluable insights into the pathophysiology. Nevertheless, translating these findings, regarding biomarkers such as miRNAs, into clinical practice requires much effort, time, and further research with a focus on validating existing evidence.
主动脉瓣狭窄（AS）是最常见的需要干预的原发性瓣膜病变。两种主要的治疗选择是手术主动脉瓣置换或经导管主动脉瓣植入。人们迫切需要能够预测治疗结果的生物标志物，并成为帮助心脏团队在决策过程中做出决策的有用工具。微小核糖核酸（microRNAs/miRs）作为近年来深入研究的潜在生物标志物而出现。在这篇综述中，我们旨在根据人体研究总结目前关于 miRNA 在 AS 中的作用的知识。迄今为止，已经进行了许多研究 miRNA 在 AS 中的作用。我们纳入了 32 项与讨论领域相关的原始人体研究。目前呈现的大多数 miRNA 仅由一个研究小组研究过。然而，有几个 miRNA 出现了不止一次，有时在不同的研究之间具有高度一致性，但有时也存在明显的差异。疾病的分子方面无疑令人兴奋，并为病理生理学提供了宝贵的见解。然而，将这些发现（例如 miRNA 等生物标志物）转化为临床实践需要付出大量的努力、时间和进一步的研究，重点是验证现有证据。
